Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib Rechallenge in mRCC
NCT02071641Phase 2Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2012
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in metastatic renal cell carcinoma (mRCC), sponsored by Amsterdam University Medical Center. Started Oct 2012; status: terminated.
02
Drugs
sunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02071641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071641.